Polymer-based therapeutics: Nanoassemblies and nanoparticles for management of atherosclerosis

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 4, 2011, Pages 400-420

  Lewis, Daniel R ^a   Kamisoglu, Kubra ^a   York, Adam W ^b   Moghe, Prabhas V ^a,c  

^a The State University of New Jersey   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIAL DISEASE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALLS; DRUG CARRIER; DYSFUNCTIONAL ENDOTHELIAL CELLS; INFLAMMATORY PROCESS; MICELLAR ASSEMBLIES; MULTI-MODAL; MULTIFOCAL; NANO-ASSEMBLIES; NANOSCALE ASSEMBLIES;

BLOOD VESSELS; DISEASES; ENDOTHELIAL CELLS; NANOPARTICLES;

FUNCTIONAL POLYMERS;

CATALASE; CD31 ANTIGEN; COLLAGEN TYPE 4; DEXTRAN; DOXORUBICIN; DRUG CARRIER; FIBRIN; FLUOROCARBON; FUMAGILLIN; GADOLINIUM PENTETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON OXIDE; LIPID; LIPOCORTIN 5; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; OXIDIZED LOW DENSITY LIPOPROTEIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYGUANYLIC ACID; POLYMER; PRAVASTATIN; TYROSINE; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; CIRCULATION; CRITICAL MICELLE CONCENTRATION; DRUG ELUTING STENT; DRUG TARGETING; ENDOTHELIUM CELL; GENE TARGETING; HUMAN; HYDROPHOBICITY; INTIMA; MACROPHAGE; MICELLE; MONOCYTE; NANOANALYSIS; NANOBIOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; CELL MEMBRANE; CORONARY ARTERY DISEASE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; INFLAMMATION; MICELLES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; TREATMENT OUTCOME;

EID: 79958253666     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.145     Document Type: Review

References (139)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. McGill HC, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological determinants of atherosclerosis in youth (PDAY) research group. Am J Cardiol 1998, 82:30T-36T.
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
4. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol 2000, 86:3J-8J; discussion 8J-9J.
5. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007, 1771:1065-1081.
6. Zinn A, Felson S, Fisher E, Schwartzbard A. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 2008, 31:397-403.
7. Staels B. Fluid retention mediated by renal PPAR[gamma]. Cell Metabolism 2005, 2:77-78.
8. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999, 19:187-195.
9. Gotto AM. Antioxidants, statins, and atherosclerosis. J Am College Cardiol 2003, 41:1205-1210.
10. Klingenberg R, Hansson GrK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009, 30:2838-2844.
11. Sheikine YA, Hansson GK. Chemokines as potential therapeutic targets in atherosclerosis. Curr Drug Targ 2006, 7:13-28.
12. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 2008, 101:S14-S19.
13. Krotz F, Sohn HY, Klauss V. Antiplatelet drugs in cardiological practice: established strategies and new developments. Vasc Health Risk Manag 2008, 4:637-645.
14. Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther 1998, 20(Suppl B):B18-B41.
15. Siu D. A new way of targeting to treat coronary artery disease. J Cardiovascular Med 2010, 11:1-6.
16. Caruso F. Nanoengineering of particle surfaces. Adv Mater 2001, 13:11-22.
17. Mailänder V, Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10:2379-2400.
18. Lowe AB, Sumerlin BS, Donovan MS, McCormick CL. Facile preparation of transition metal nanoparticles stabilized by well-defined (co)polymers synthesized via aqueous reversible addition-fragmentation chain transfer polymerization. J Am Chem Soc 2002, 124:11562-11563.
19. Sumerlin BS, Lowe AB, Stroud PA, Zhang P, Urban MW, McCormick CL. Modification of gold surfaces with water-soluble (co)polymers prepared via aqueous reversible addition-fragmentation chain transfer (RAFT) polymerization. Langmuir 2003, 19:5559-5562.
20. Ranjan R, Brittain WJ. Combination of living radical polymerization and click chemistry for surface modification. Macromolecules 2007, 40:6217-6223.
21. Balazs AC, Emrick T, Russell TP. Nanoparticle polymer composites: where two small worlds meet. Science 2006, 314:1107-1110.
22. Anton N, Benoit J-P, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 2008, 128:185-199.
23. Hornig S, Heinze T, Becer CR, Schubert US. Synthetic polymeric nanoparticles by nanoprecipitation. J Mater Chem 2009, 19:3838-3840.
24. Johnson BK, Prud'homme RK. Flash nanoprecipitation of organic actives and block copolymers using a confined impinging jets mixer. Aust J Chem 2003, 56:1021-1024.
25. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989, 55:R1-R4.
26. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
27. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
28. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
29. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharma 2008, 47:619-634.
30. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992, 267:18759-18765.
31. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
32. Sharma G, Valenta DT, Altman Y, Harvey S, Xie H, Mitragotri S, Smith JW. Polymer particle shape independently influences binding and internalization by macrophages. J Cont Rel 2010, 147:408-412.
33. Lehn J-M. Supramolecular polymer chemistry-scope and perspectives. Polym Int 2002, 51:825-839.
34. Haag R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew Chem Int Ed 2004, 43:278-282.
35. Shimizu T, Masuda M, Minamikawa H. Supramolecular nanotube architectures based on amphiphilic molecules. Chem Rev 2005, 105:1401-1444.
36. Broz P, Marsch S, Hunzikel P. Targeting of vulnerable plaque macrophages with polymer-based nanostructures. Trends Cardiovas Med 2007, 17:190-196.
37. Chen W, Cormode DP, Fayad ZA, Mulder WJM. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. WIREs Nanomed Nanobiotechnol 2010. doi:10.1002/wnan.114.
38. Mulder WJM, Strijkers GJ, van Tilborg GAF, Cormode DP, Fayad ZA, Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 2009, 42:904-914.
39. Iverson NM, Sparks SM, Demirdirek B, Uhrich KE, Moghe PV. Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers. Acta Biomater 2010, 6:3081-3091.
40. Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology and cardiovascular medicine: progress and emerging prospects. BioDrugs 2008, 22:1-10.
41. Chnari E, Nikitczuk JS, Uhrich KE, Moghe PV. Nanoscale anionic macromolecules can inhibit cellular uptake of differentially oxidized LDL. Biomacromolecules 2006, 7:597-603.
42. Plourde NM, Kortagere S, Welsh W, Moghe PV. Structure-activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor A. Biomacromolecules 2009, 10:1381-1391.
43. Kearney AS. Prodrugs and targeted delivery. Adv Drug Deliv Rev 1996, 19:225-239.
44. Kabanov AV, Kabanov VA. Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects. Adv Drug Deliv Rev 1998, 30:49-60.
45. Christie RJ, Grainger DW. Design strategies to improve soluble macromolecular delivery constructs. Adv Drug Delivery Rev 2003, 55:421-437.
46. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discovery 2005, 4:581-593.
47. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Delivery Rev 2005, 57:2147-2162.
48. Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Delivery Rev 2005, 57:609-636.
49. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Delivery Rev 2005, 57:2106-2129.
50. Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery-past, present, and future. Prog Polym Sci 2007, 32:799-837.
51. York AW, Kirkland SE, McCormick CL. Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1018-1036.
52. Lutz J-F, Börner HG. Modern trends in polymer bioconjugates design. Prog Polym Sci 2008, 33:1-39.
53. Lusis AJ. Atherosclerosis. Nature 2000, 407: 233-241.
54. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. P Natl Acad Sci USA 1979, 76:333-337.
55. Mulder WJM, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JGS, Vucic E, Amirbekian V, Tang C, Chin PTK, Nicolay K, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007, 58:1164-1170.
56. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovascul Pharmacol 2008, 51:246-252. doi:10.1097/FJC.0b013e3181624aed.
57. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JGS, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961-966.
58. van Tilborg GAF, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, Reutelingsperger CPM, Fayad ZA, Mulder WJM, Nicolay K. Annexin A5-functionalized bimodal nanoparticles for mri and fluorescence imaging of atherosclerotic plaques. Bioconjugate Chem 2010, 21:1794-1803.
59. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 2009, 106:9815-9819.
60. Chnari E, Nikitczuk JS, Wang J, Uhrich KE, Moghe PV. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 2006, 7:1796-1805.
61. Chnari E, Lari HB, Tian L, Uhrich KE, Moghe PV. Nanoscale anionic macromolecules for selective retention of low-density lipoproteins. Biomaterials 2005, 26:3749-3758.
62. Jones M-C, Leroux J-C. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999, 48:101-111.
63. Discher DE, Eisenberg A. Polymer vesicles. Science 2002, 297:967-973.
64. Discher BM, Won Y-Y, Ege DS, Lee JCM, Bates FS, Discher DE, Hammer DA. Polymersomes: tough vesicles made from diblock copolymers. Science 1999, 284:1143-1146.
65. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 1996, 21:107-116.
66. Riess G. Micellization of block copolymers. Prog Polym Sci 2003, 28:1107-1170.
67. Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006, 8:323-341.
68. Morishima Y, Nomura S, Ikeda T, Seki M, Kamachi M. Characterization of unimolecular micelles of random copolymers of sodium 2-(acrylamido)-2-methylpropanesulfonate and methacrylamides bearing bulky hydrophobic substituents. Macromolecules 1995, 28:2874-2881.
69. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004, 56:1273-1289.
70. Li F, Danquah M, Mahato RI. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules 2010, 11:2610-2620.
71. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Therapeut 2006, 112:630-648.
72. Dash PR, Read ML, Barrett LB, Wolfert MA, Seymour LW. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther 1999, 6:643-650.
73. Li Y, Lokitz BS, Armes S, McCormick CL. Synthesis of reversible shell cross-linked micelles for controlled release of bioactive agents. Macromolecules 2006, 39:2726-2728.
74. Wooley KL. Shell crosslinked polymer assemblies: Nanoscale constructs inspired from biological systems. J Polym Sci A: Polym Chem 2000, 38:1397-1407.
75. Read ES, Armes SP. Recent advances in shell cross-linked micelles. Chem Commun 2007, 3021-3035.
76. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005, 2:319-327.
77. Tian L, Yam L, Zhou N, Tat H, Uhrich KE. Amphiphilic scorpion-like macromolecules: design, synthesis, and characterization. Macromolecules 2004, 37:538-543.
78. Briley-Saebo KC, Shaw PX, Mulder WJM, Choi S-H, Vucic E, Aguinaldo JGS, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117:3206-3215.
79. Beilvert A, Cormode DP, Chaubet F, Briley-Saebo KC, Mani V, Mulder WJ, Vucic E, Toussaint JF, Letourneur D, Fayad ZA. Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med 2009, 62:1195-1201.
80. McCormick CL, Sumerlin BS, Lokitz BS, Stempka JE. RAFT-synthesized diblock and triblock copolymers: thermally-induced supramolecular assembly in aqueous media. Soft Matter 2008, 4:1760-1773.
81. McCormick CL, York AW, Kirkland SE. Synthetic routes to stimuli-responsive micelles, vesicles, and surfaces via controlled/living radical polymerization. Poly Rev 2006, 46:421-443.
82. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Col Cardiol 2007, 49:2073-2080.
83. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005, 96:327-336.
84. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
85. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
86. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with {α}ν{β}3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
87. McCarthy J, Jaffer F, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2006, 2:983-987.
88. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
89. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, et al. Endothelial {α}{ν}{β}3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2103-2109.
90. Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H, Simone E, Nakada MT, Fisher A, Albelda SM, et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 2008, 29:215-227.
91. Ikuta K, Mori T, Yamamoto T, Niidome T, Shimokawa H, Katayama Y. Development of polymeric drug delivery system for recognizing vascular endothelial dysfunction. Bioorgan Med Chem 2008, 16:2811-2818.
92. Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee J-W, Cheng J, Golomb G, Libby P, Langer R, Farokhzad OC. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci 2010, 107:2213-2218.
93. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs 2005, 8:77-84.
94. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005, 1:47-64.
95. Uwatoku T, Shimokawa H, Abe K, Matsumoto Y, Hattori T, Oi K, Matsuda T, Kataoka K, Takeshita A. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res 2003, 92:e62-e69.
96. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. Mol Interv 2006, 6:98-112.
97. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003, 116:1599-1609.
98. Muro S, Cui XM, Gajewski C, Murciano JC, Muzykantov VR, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol-Cell Ph 2003, 285:C1339-C1347.
99. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 1992, 140:665-673.
100. Garnacho C, Dhami R, Simone E, Dziubla T, Leferovich J, Schuchman EH, Muzykantov V, Muro S. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther 2008, 325:400-408.
101. Muro S, Dziubla T, Qiu WN, Leferovich J, Cui X, Berk E, Muzykantov VR. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 2006, 317:1161-1169.
102. Murciano JC, Muro S, Koniaris L, Christofidou-Solomiclou M, Harshaw DW, Albelda SM, Granger DN, Cines DB, Muzykantov VR. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003, 101:3977-3984.
103. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of icam-1-targeted carriers. Mo Ther 2008, 16:1450-1458.
104. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconj Chem 2008, 19:145-152.
105. Tibbetts SA, Jois DSS, Siahaan TJ, Benedict SH, Chan MA. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides 2000, 21:1161-1167.
106. Yusuf-Makagiansar H, Siahaan TJ. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharma Res 2001, 18:329-335.
107. Simone E, Ding BS, Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res 2009, 335:283-300.
108. Molenaar TJM, Twisk J, de Haas SAM, Peterse N, Vogelaar BJCP, van Leeuwen SH, Michon IN, van Berkel TJC, Kuiper J, Biessen EAL. P-selectin as a candidate target in atherosclerosis. Biochem Pharmacol 2003, 66:859-866.
109. Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA. Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest 2006, 86:599-609.
110. McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, Greaves DR, Neubauer S, Channon KM, Choudhury RP. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol 2008, 28:77-83.
111. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J Am College Cardiol 2007, 49:2093-2101.
112. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann Med 2008, 40:606-621.
113. Smirnov VN, Domogatsky SP, Dolgov VV, Hvatov VB, Klibanov AL, Koteliansky VE, Muzykantov VR, Repin VS, Samokhin GP, Shekhonin BV. Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. Proc Natl Acad Sci U S A 1986, 83:6603.
114. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006, 26:1702-1711.
115. Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, Yoshimoto R, Sawamura T. LOX-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J 2009, 73:1993-1999.
116. Wang J, Plourde NM, Iverson N, Moghe PV, Uhrich KE. Nanoscale amphiphilic macromolecules as lipoprotein inhibitors: the role of charge and architecture. Int J Nanomed 2007, 2:697-705.
117. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Horkko S, Palinski W, Quehenberger O, Shaw P, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001, 947:214-222, discussion 222-223
118. White SJ, Nicklin SA, Sawamura T, Baker AH. Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension 2001, 37:449-455.
119. Wang L, Bao Y, Yang Y, Wu Y, Chen X, Si S, Hong B. Discovery of antagonists for human scavenger receptor cd36 via an elisa-like high-throughput screening assay. J Biomol Screen 2010, 15:239-250.
120. Azzazy HME, Highsmith WE. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002, 35:425-445.
121. Liu J, Weller GER, Zern B, Ayyaswamy PS, Eckmann DM, Muzykantov VR, Radhakrishnan R. Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci 2010, 107:16530.
122. Decuzzi P, Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
123. Bijsterbosch MK, van Berkel TJC. Native and modified lipoproteins as drug delivery systems. Adv Drug Delivery Rev 1990, 5:231-251.
124. Nikitina N, Khalilov E, Torkhovskaya T, Tertov V, Orekhov A. Polyunsaturated phosphatidylcholine micelle-induced decrease of atherogenicity of the serum in vitro. Bull Exp Biol Med 1995, 119:480-483.
125. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
126. Joner M, Morimoto K, Kasukawa H, Steigerwald K, Merl S, Nakazawa G, John MC, Finn AV, Acampado E, Kolodgie FD, et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 2008, 28:1960-1966.
127. Lanza G, Winter P, Caruthers S, Hughes M, Hu G, Schmieder A, Wickline S. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010, 13:189-202.
128. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J Am Coll Cardiol Img 2008, 1:624-634.
129. Bai S, Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res 2009, 26:539-548.
130. Akagi D, Oba M, Koyama H, Nishiyama N, Fukushima S, Miyata T, Nagawa H, Kataoka K. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther 2007, 14:1029-1038.
131. Padoveze AF, Maniero F, Oliveira TV, Vitorio TS, Couto RD, Maranhão RC. Effect of a cholesterol-rich diet on the metabolism of the free and esterified cholesterol components of a nanoemulsion that resembles LDL in rabbits. Brazil J Med Biol Res 2009, 42:172-178.
132. Mackiewicz MR, Hodges HL, Reed SM. C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. J Phys Chem B 2010, 114:5556-5562.
133. Buono C, Anzinger JJ, Amar M, Kruth HS. Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions. J Clin Invest 2009, 119:1373-1381.
134. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004, 3:913-925.
135. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99:2293-2352.
136. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf K-J. Superparamagnetic iron oxide-enhanced mri of atherosclerotic plaques in watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000, 35:460-471.
137. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?". J Am Coll Cardiol 2009, 53:2051-2052.
138. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13:636-641.
139. Smith AM, Mancini MC, Nie S. Bioimaging: second window for in vivo imaging. Nat Nanotechnol 2009, 4:710-711.